Omidria approved for pediatric patients

The FDA has expanded the indication for Omidria, a mydriatic and NSAID combination agent, to include use in pediatric patients from birth through 17 years.
Source: Daily Dose of Eye Care

https://www.lvcenter4sight.com/omidria-approved-for-pediatric-patients/

Comments

Popular posts from this blog

FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10

Cataract Surgery Leads to Longer Life in Women

Vision Improvements Reported in ProQR’s Clinical Trial for LCA10 Treatment